Company Overview - Penumbra, Inc. (NYSE:PEN) is a global leader in thrombectomy and vascular intervention technologies, offering products such as the Indigo and Lightning series, and neuro and vascular embolization solutions [1] - The company operates in over 100 countries, serving acute stroke and broader vascular markets through both direct and distributor-driven channels [1] Leadership and Innovation - In September 2025, Shruthi Narayan was promoted to President, bringing engineering and commercialization expertise to strengthen PEN's focus on global innovation and market growth [2] - The introduction of the Ruby XL System, the largest and longest detachable embolization coil, demonstrates versatility in complex vascular procedures and supports wider clinical adoption [2] Product Development and Clinical Trials - Penumbra expanded its thrombectomy capabilities with the release of the Lightning Bolt 6X device in a 150 cm length, enabling Computer Assisted Vacuum Thrombectomy (CAVT) in smaller, distal vessels, which is critical for peripheral arterial disease interventions [3] - The firm completed enrollment for the STORM-PE Randomized Controlled Trial, evaluating CAVT's effectiveness in pulmonary embolism, with results expected to influence future treatment guidelines and expand market penetration [3] Commitment to Healthcare Efficiency - Penumbra remains committed to advancing minimally invasive clot removal technologies that improve patient outcomes while enhancing healthcare efficiency [4] - Recent clinical data highlights the speed, safety, and efficacy of its CAVT devices, reinforcing growth potential in both U.S. and international markets [4]

Core Insights - The article discusses the 12 best healthcare stocks to buy and hold for five years, highlighting the role of AI in improving healthcare services and addressing insurance denials [1][4]. Group 1: AI in Healthcare - Dr. Warris Bokhari's platform utilizes AI to appeal health insurance denials for approximately 70 autoimmune diseases, addressing a significant issue where 850 million denials occur annually in the U.S. [2][3]. - The platform was launched on October 2, 2024, and aims to assist patients in navigating care denials by generating appeal letters based on healthcare plans [4]. Group 2: Stock Selection Methodology - The selection of the top healthcare stocks was based on criteria including EPS growth of over 10% in the past five years, an expected EPS growth rate of at least 20% over the next five years, and a forward PE ratio greater than 20 [6]. - The final ranking of stocks was influenced by the number of hedge fund holders as tracked by the Insider Monkey database as of Q2 2025 [6][7]. Group 3: Company Highlights - **Intuitive Surgical, Inc. (NASDAQ:ISRG)**: Pioneered robotic-assisted minimally invasive surgery with its da Vinci systems, which are used globally. The company introduced advanced software features for its da Vinci 5 system in September 2025, enhancing surgical capabilities [9][10]. - **Doximity, Inc. (NYSE:DOCS)**: A leading healthcare technology stock that completed the acquisition of Pathway Medical, enhancing its AI-driven tools. The company reported a 15% year-over-year revenue increase, reaching $145.9 million for the quarter ending June 30, 2025 [13][15]. - **Penumbra, Inc. (NYSE:PEN)**: A leader in thrombectomy and vascular intervention technologies, recently introduced the Ruby XL System and the Lightning Bolt 6X device, expanding its product offerings and market reach [16][18].